Identifying altered genes in lung cancer tumors and using this treatment to target therapy for treating the disease has transformed the approach of cancer treatment. A new study describes testing lung tumors on a national scale, not only to identify the cancer but also for several different genetic mutations in the tumor cells. This is allowing doctors to target therapy to better treat the disease. Catherine Dolf explains in this week’s JAMA Report.

Read the JAMA report here:

Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs